Impact of Smoking on Cardiovascular Events in Patients With Established Coronary Disease Receiving Contemporary Medical Therapy: a Post Hoc Analysis of the Treating to New Targets (TNT) & the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Trials

被引：0
|
作者：
Frey, Paul F.
Waters, David D.
DeMicco, David A.
Breazna, Andrei
Samuels, Larry
Pipe, Andrew L.
Benowitz, Neal L.
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Pfizer, New York, NY USA
[3] Pfizer Inc, New York, NY USA
[4] Univ Ottawa, Ottawa, ON, Canada
来源：
CIRCULATION | 2010年 / 122卷 / 21期
关键词：
Smoking; Statins; Cardiovascular disease prevention;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A13483
引用
收藏
页数：2
相关论文
共 11 条
  • [1] Impact of Smoking on Cardiovascular Events in Patients With Coronary Disease Receiving Contemporary Medical Therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trials)
    Rocha, Evangelista
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2011, 30 (01) : 125 - 128
  • [2] Impact of Smoking on Cardiovascular Events in Patients With Coronary Disease Receiving Contemporary Medical Therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trials)
    Frey, Paul
    Waters, David D.
    DeMicco, David A.
    Breazna, Andrei
    Samuels, Larry
    Pipe, Andrew
    Wun, Chuan-Chuan
    Benowitz, Neal L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 107 (02): : 145 - 150
  • [3] Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease
    Faergeman, Ole
    Holme, Ingar
    Fayyad, Rana
    Bhatia, Sonal
    Grundy, Scott M.
    Kastelein, John J. P.
    LaRosa, John C.
    Larsen, Mogens Lytken
    Lindahl, Christina
    Olsson, Anders G.
    Tikkanen, Matti J.
    Waters, David D.
    Pedersen, Terje R.
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (04): : 459 - 463
  • [4] Impact of smoking on cardiovascular events in patients with stable coronary disease receiving contemporary medical therapy: a post hoc analysis of the Treating to New Targets trial
    Frey, P.
    Waters, D.
    Pipe, A.
    Demicco, D.
    Breazna, A.
    Samuels, L.
    Benowitz, N. L.
    EUROPEAN HEART JOURNAL, 2010, 31 : 372 - 372
  • [5] Superiority of ApoB/ApoA1 ratio for predicting cardiovascular risk in pooled analyses of the incremental decrease in endpoints through aggressive lipid-lowering (IDEAL) and treating to new targets (TNT) trials
    Kastelein, John J.
    Holme, Ingar
    Barter, Philip
    Olsson, Anders G.
    Cater, Nilo B.
    DeMicco, David A.
    Gaffney, Michael
    Szarek, Michael
    LaRosa, John C.
    Pedersen, Terje R.
    CIRCULATION, 2006, 114 (18) : 713 - 714
  • [6] Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL)
    Holme, Ingar
    Cater, Nilo B.
    Faergeman, Ole
    Kastelein, John J. P.
    Olsson, Anders G.
    Tikkanen, Matti J.
    Larsen, Mogens Lytken
    Lindahl, Christina
    Pedersen, Terje R.
    ANNALS OF MEDICINE, 2008, 40 (06) : 456 - 464
  • [7] Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy Insights From the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) Trial
    Tikkanen, Matti J.
    Szarek, Michael
    Fayyad, Rana
    Holme, Ingar
    Cater, Nilo B.
    Faergeman, Ole
    Kastelein, John J. P.
    Olsson, Anders G.
    Larsen, Mogens Lytken
    Lindahl, Christina
    Pedersen, Terje R.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (25) : 2353 - 2357
  • [8] The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies
    Arsenault, Benoit J.
    Boekholdt, S. Matthijs
    Hovingh, G. Kees
    Hyde, Craig L.
    DeMicco, David A.
    Chatterjee, Aurobindo
    Barter, Philip
    Deedwania, Prakash
    Waters, David D.
    LaRosa, John C.
    Pedersen, Terje R.
    Kastelein, John J. P.
    CIRCULATION-CARDIOVASCULAR GENETICS, 2012, 5 (01) : 51 - 57
  • [9] Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL)
    Holme, Ingar
    Strandberg, Timo E.
    Faergeman, Ole
    Kastelein, John J. P.
    Olsson, Anders G.
    Tikkanen, Matti J.
    Larsen, Mogens Lytken
    Lindahl, Christina
    Pedersen, Terje R.
    ATHEROSCLEROSIS, 2009, 205 (02) : 522 - 527
  • [10] Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)
    Pedersen, Terje R.
    Cater, Nilo B.
    Faergeman, Ole
    Kastelein, John J. P.
    Olsson, Anders G.
    Tikkanen, Matti J.
    Holme, Ingar
    Larsen, Mogens Lytken
    Lindahl, Christina
    Szarek, Michael
    AMERICAN JOURNAL OF CARDIOLOGY, 2010, 106 (03): : 354 - 359
12